CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Axitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02579811
NCT02579811Phase 2Completed
CompareCT.gov

A Phase II Study of the Efficacy and Safety of Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer After Treatment With Pd-1 or Pd-L1 Inhibitors

Case Comprehensive Cancer Center·interventional·Posted Oct 20, 2015·Updated Jun 29, 2023

In Brief

A Phase 2 clinical trial evaluating Axitinib for Metastatic Renal Cell Cancer. Completed, enrolled 40 participants across 4 sites.

Detailed Summary

Axitinib is a drug which is approved by the FDA for patients with advanced kidney cancer who have already received some treatment. It works by reducing blood flow to a tumor. Axitinib is normally give at 5mg twice per day and sometimes this dose is increased if patients tolerate it. The purpose of this study is to figure out a different way to decide which dose of axitinib each patient should receive based on the side effects they experience.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Renal Cell Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 20, 2015
Enrollment StartDec 30, 2015
Primary CompletionAug 21, 2019
Study CompletionJun 20, 2023
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 10.7 years ago

Interventions

Axitinibdrug

The intent is to maximize sustained dose intensity of axitinib based on individual tolerability using dose modification criteria